Entry Instance

HTTP 200 OK
Allow: GET, PUT, PATCH, DELETE, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "id": 1527636,
    "url": "https://info.mzalendo.com/api/v0.1/hansard/entries/1527636/?format=api",
    "text_counter": 40,
    "type": "speech",
    "speaker_name": "Sen. Wakili Sigei",
    "speaker_title": "",
    "speaker": null,
    "content": "Mr Speaker, Sir, I rise pursuant to Standing Order No.53 (1), to seek a Statement from the Standing Committee on Health regarding the easy accessibility and illegal sale of the diabetes prescription injectable drug, namely Ozempic, which is sold over the counter in the Kenyan market as semaglutide to be used for quick weight loss. Diabetes is a growing public health concern in Kenya, with patients relying on prescribed medications to manage the condition effectively. However, there is concern on the widespread over-the-counter sales of Ozempic injectable for use as a weight loss agent, with total disregard to the severe side effects, drug interactions and long-term complications, including the hypoglycemia and organ damage that may occur. In the Statement, the Committee should- (1) Highlight the regulatory measures in place that are intended to ensure that the sale of all prescription drugs, including Ozempic, are only dispensed at registered chemists and pharmacies, upon the production of a valid prescription following a medical consultation. (2) State the steps being taken by the Pharmacy and Poisons Board to ensure that the regulations on the sale and distribution of medicine, specifically prescription drugs such as Ozempic, are strictly adhered to. (3) State any interventions in place to – (a) Monitor, track and curb the illegal over-the-counter sale and distribution of"
}